 Amir Jaffer
Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 32 | 2019 | 151 | 6.550 |
Why?
| | Perioperative Care | 19 | 2017 | 75 | 4.640 |
Why?
| | Venous Thromboembolism | 13 | 2019 | 53 | 3.770 |
Why?
| | Warfarin | 17 | 2019 | 60 | 2.830 |
Why?
| | Thromboembolism | 14 | 2015 | 37 | 2.750 |
Why?
| | Heparin, Low-Molecular-Weight | 15 | 2015 | 24 | 2.270 |
Why?
| | Surgical Procedures, Operative | 7 | 2017 | 40 | 1.780 |
Why?
| | Venous Thrombosis | 9 | 2017 | 51 | 1.440 |
Why?
| | Atrial Fibrillation | 9 | 2016 | 197 | 1.380 |
Why?
| | Postoperative Complications | 14 | 2015 | 1083 | 1.300 |
Why?
| | Hospital Medicine | 2 | 2017 | 2 | 1.110 |
Why?
| | Quality of Health Care | 3 | 2017 | 141 | 1.020 |
Why?
| | Hospitalists | 2 | 2017 | 7 | 0.940 |
Why?
| | Polysaccharides | 7 | 2009 | 20 | 0.920 |
Why?
| | Risk Factors | 24 | 2017 | 2664 | 0.900 |
Why?
| | Hemorrhage | 10 | 2019 | 90 | 0.880 |
Why?
| | Risk Assessment | 16 | 2016 | 806 | 0.880 |
Why?
| | Elective Surgical Procedures | 6 | 2017 | 55 | 0.810 |
Why?
| | Humans | 58 | 2022 | 31481 | 0.790 |
Why?
| | Cardiac Surgical Procedures | 3 | 2009 | 98 | 0.750 |
Why?
| | Platelet Aggregation Inhibitors | 4 | 2013 | 62 | 0.610 |
Why?
| | Heparin | 5 | 2008 | 37 | 0.600 |
Why?
| | Arthroplasty, Replacement, Hip | 6 | 2019 | 840 | 0.600 |
Why?
| | Cooperative Behavior | 1 | 2017 | 86 | 0.590 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2015 | 29 | 0.590 |
Why?
| | Hematologic Diseases | 1 | 2016 | 17 | 0.580 |
Why?
| | Arthroplasty, Replacement, Knee | 6 | 2019 | 668 | 0.560 |
Why?
| | Preoperative Care | 4 | 2009 | 146 | 0.550 |
Why?
| | Quality Improvement | 2 | 2016 | 173 | 0.540 |
Why?
| | Fibrinolytic Agents | 5 | 2016 | 99 | 0.510 |
Why?
| | Withholding Treatment | 2 | 2015 | 10 | 0.500 |
Why?
| | Postoperative Hemorrhage | 2 | 2012 | 31 | 0.480 |
Why?
| | Hospitalization | 4 | 2010 | 359 | 0.480 |
Why?
| | Postoperative Care | 3 | 2009 | 141 | 0.480 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 15 | 0.470 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2014 | 45 | 0.470 |
Why?
| | Intraoperative Care | 2 | 2009 | 58 | 0.430 |
Why?
| | Practice Guidelines as Topic | 3 | 2015 | 389 | 0.420 |
Why?
| | Female | 22 | 2019 | 18253 | 0.390 |
Why?
| | Patient Care Team | 2 | 2014 | 153 | 0.380 |
Why?
| | Aged | 17 | 2019 | 10295 | 0.370 |
Why?
| | Evidence-Based Medicine | 4 | 2013 | 239 | 0.360 |
Why?
| | United States | 6 | 2017 | 2539 | 0.330 |
Why?
| | Patient Readmission | 3 | 2017 | 129 | 0.330 |
Why?
| | Thrombosis | 3 | 2013 | 67 | 0.320 |
Why?
| | Myocardial Ischemia | 1 | 2008 | 63 | 0.320 |
Why?
| | Physician's Role | 1 | 2007 | 22 | 0.310 |
Why?
| | Time Factors | 7 | 2016 | 1902 | 0.300 |
Why?
| | Male | 15 | 2019 | 17583 | 0.300 |
Why?
| | Hip Fractures | 1 | 2006 | 30 | 0.300 |
Why?
| | Administration, Oral | 3 | 2016 | 164 | 0.280 |
Why?
| | Antithrombins | 1 | 2005 | 6 | 0.270 |
Why?
| | Stroke | 3 | 2016 | 367 | 0.270 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 257 | 0.260 |
Why?
| | Heart Failure | 1 | 2008 | 232 | 0.260 |
Why?
| | Incidence | 4 | 2015 | 829 | 0.260 |
Why?
| | Vena Cava Filters | 3 | 2009 | 10 | 0.250 |
Why?
| | Hirudins | 2 | 2014 | 2 | 0.250 |
Why?
| | International Normalized Ratio | 2 | 2019 | 32 | 0.230 |
Why?
| | Aspirin | 5 | 2012 | 90 | 0.220 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 59 | 0.210 |
Why?
| | Enoxaparin | 3 | 2012 | 9 | 0.200 |
Why?
| | Societies, Medical | 2 | 2013 | 209 | 0.200 |
Why?
| | Aged, 80 and over | 7 | 2014 | 5234 | 0.190 |
Why?
| | Predictive Value of Tests | 3 | 2016 | 637 | 0.180 |
Why?
| | American Heart Association | 2 | 2009 | 39 | 0.180 |
Why?
| | Vitamin K | 3 | 2012 | 11 | 0.180 |
Why?
| | Length of Stay | 2 | 2013 | 377 | 0.170 |
Why?
| | Odds Ratio | 5 | 2016 | 327 | 0.170 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1997 | 3 | 0.160 |
Why?
| | Treatment Outcome | 7 | 2016 | 3910 | 0.160 |
Why?
| | Puerperal Disorders | 1 | 1997 | 9 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2022 | 3591 | 0.160 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 42 | 0.160 |
Why?
| | Heart Valve Prosthesis | 3 | 2012 | 44 | 0.150 |
Why?
| | Lung Diseases | 2 | 2014 | 54 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2019 | 2028 | 0.150 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 2016 | 7 | 0.150 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2016 | 18 | 0.150 |
Why?
| | Telemetry | 1 | 2016 | 15 | 0.150 |
Why?
| | Genotype | 1 | 2017 | 423 | 0.140 |
Why?
| | Primary Health Care | 1 | 2017 | 106 | 0.140 |
Why?
| | Prognosis | 3 | 2011 | 1028 | 0.140 |
Why?
| | Heart Rate | 1 | 2016 | 161 | 0.140 |
Why?
| | Patient Selection | 4 | 2016 | 264 | 0.140 |
Why?
| | Middle Aged | 8 | 2017 | 11209 | 0.130 |
Why?
| | Cardiovascular Diseases | 3 | 2014 | 410 | 0.130 |
Why?
| | Comorbidity | 2 | 2008 | 562 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2012 | 1240 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2014 | 103 | 0.130 |
Why?
| | Pulmonary Embolism | 1 | 2014 | 57 | 0.130 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2013 | 2 | 0.120 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 6 | 0.120 |
Why?
| | Pyridines | 2 | 2016 | 50 | 0.120 |
Why?
| | Chile | 1 | 2013 | 1 | 0.120 |
Why?
| | Neoplasms | 2 | 2008 | 280 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2014 | 146 | 0.120 |
Why?
| | Adult | 7 | 2017 | 9779 | 0.110 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2013 | 81 | 0.110 |
Why?
| | Risk Reduction Behavior | 3 | 2008 | 59 | 0.110 |
Why?
| | Stents | 2 | 2012 | 155 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 1 | 1997 | 1273 | 0.110 |
Why?
| | Disease Management | 2 | 2015 | 147 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2011 | 187 | 0.100 |
Why?
| | Drug Synergism | 1 | 2009 | 67 | 0.090 |
Why?
| | Premedication | 2 | 2006 | 6 | 0.090 |
Why?
| | Medication Therapy Management | 1 | 2008 | 6 | 0.090 |
Why?
| | Prodrugs | 1 | 2008 | 5 | 0.090 |
Why?
| | Azetidines | 1 | 2008 | 4 | 0.090 |
Why?
| | Benzylamines | 1 | 2008 | 15 | 0.090 |
Why?
| | Ohio | 1 | 2008 | 10 | 0.080 |
Why?
| | Age Factors | 2 | 2014 | 943 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2008 | 15 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 230 | 0.080 |
Why?
| | Stroke Volume | 1 | 2008 | 64 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2007 | 29 | 0.080 |
Why?
| | Cause of Death | 1 | 2008 | 78 | 0.080 |
Why?
| | Thrombolytic Therapy | 1 | 2008 | 85 | 0.080 |
Why?
| | Colorado | 1 | 2007 | 5 | 0.080 |
Why?
| | Echocardiography | 1 | 2008 | 197 | 0.080 |
Why?
| | Evaluation Studies as Topic | 1 | 2007 | 60 | 0.080 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 110 | 0.080 |
Why?
| | Chemoprevention | 1 | 2006 | 7 | 0.080 |
Why?
| | Delirium | 1 | 2006 | 41 | 0.080 |
Why?
| | Survival Rate | 1 | 2008 | 465 | 0.070 |
Why?
| | Bariatric Surgery | 1 | 2006 | 43 | 0.070 |
Why?
| | Lung | 1 | 2006 | 171 | 0.070 |
Why?
| | Primary Prevention | 1 | 2006 | 53 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2006 | 76 | 0.070 |
Why?
| | Probability | 1 | 2005 | 104 | 0.070 |
Why?
| | Survival Analysis | 1 | 2006 | 379 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2005 | 67 | 0.070 |
Why?
| | Disease Progression | 1 | 2008 | 861 | 0.070 |
Why?
| | Prospective Studies | 1 | 2010 | 1934 | 0.060 |
Why?
| | Postmenopause | 1 | 2004 | 66 | 0.060 |
Why?
| | Orthopedic Procedures | 1 | 2008 | 322 | 0.060 |
Why?
| | Geriatric Assessment | 1 | 2006 | 232 | 0.060 |
Why?
| | Hormone Replacement Therapy | 1 | 2004 | 46 | 0.060 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2003 | 12 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2005 | 378 | 0.060 |
Why?
| | Decision Making | 1 | 2006 | 232 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2003 | 75 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2014 | 295 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 375 | 0.060 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 26 | 0.050 |
Why?
| | Outpatients | 1 | 2022 | 56 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 136 | 0.050 |
Why?
| | Hospitals | 1 | 2022 | 142 | 0.050 |
Why?
| | Injections, Subcutaneous | 2 | 2012 | 41 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 301 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 412 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 390 | 0.040 |
Why?
| | Adolescent | 2 | 2012 | 2667 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2017 | 15 | 0.040 |
Why?
| | Jugular Veins | 1 | 1997 | 6 | 0.040 |
Why?
| | Drug Interactions | 1 | 2017 | 70 | 0.040 |
Why?
| | Cranial Sinuses | 1 | 1997 | 9 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 1997 | 51 | 0.040 |
Why?
| | Medicaid | 1 | 2017 | 43 | 0.040 |
Why?
| | Pyridones | 1 | 2016 | 19 | 0.040 |
Why?
| | Medicare | 1 | 2017 | 113 | 0.040 |
Why?
| | Thiazoles | 1 | 2016 | 38 | 0.040 |
Why?
| | Regression Analysis | 1 | 2017 | 319 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2016 | 44 | 0.040 |
Why?
| | Pyrazoles | 1 | 2016 | 55 | 0.040 |
Why?
| | Focus Groups | 1 | 2016 | 93 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2015 | 559 | 0.040 |
Why?
| | Perioperative Period | 1 | 2015 | 13 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 106 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 60 | 0.030 |
Why?
| | Clonidine | 1 | 2014 | 31 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2016 | 130 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2014 | 53 | 0.030 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 42 | 0.030 |
Why?
| | Heart Arrest | 1 | 2014 | 48 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 986 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 64 | 0.030 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2014 | 72 | 0.030 |
Why?
| | Postoperative Period | 1 | 2014 | 295 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2012 | 73 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2004 | 687 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 230 | 0.030 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2012 | 52 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 26 | 0.030 |
Why?
| | Logistic Models | 1 | 2012 | 479 | 0.030 |
Why?
| | Ticlopidine | 1 | 2008 | 14 | 0.020 |
Why?
| | Butanones | 1 | 1987 | 1 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 512 | 0.020 |
Why?
| | Health Personnel | 1 | 2008 | 108 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1987 | 111 | 0.020 |
Why?
| | Young Adult | 1 | 2012 | 2277 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2004 | 58 | 0.020 |
Why?
| | Time | 1 | 2004 | 22 | 0.020 |
Why?
| | Acute Disease | 1 | 2004 | 254 | 0.020 |
Why?
| | Osteoarthritis | 1 | 1987 | 369 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2004 | 390 | 0.010 |
Why?
| | Patient Dropouts | 1 | 1987 | 31 | 0.010 |
Why?
| | Random Allocation | 1 | 1987 | 164 | 0.000 |
Why?
|
|
Jaffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|